Effects of gamma-interferon and FK506 on resting B cell proliferation of New Zealand black/white F1 mice.
We examined the effects of gamma-interferon (gamma-IFN) and the new immunosuppressant FK506 on resting B cell proliferation of New Zealand black/white F1 hybrid (B/W F1) mice, an animal model of human systemic lupus erythematosus (SLE). gamma-IFN and FK506 inhibited in a dose-dependent manner both B cell proliferation and autoantibody production of resting B cells respectively. There was a synergistic interaction between gamma-IFN and FK506 in their inhibition and they did not exhibit cell cytotoxicity. This in vitro synergism of gamma-IFN and FK506 may have clinical application in that low doses of gamma-IFN and FK506 combinations may be effective to correct polyclonal B cell activation of patients with SLE.
D000818:Animals; D001402:B-Lymphocytes / Q000187:drug effects*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004247:DNA / Q000276:immunology; D004357:Drug Synergism; D005260:Female; D006824:Hybridization, Genetic; D007371:Interferon-gamma / Q000494:pharmacology*; D015847:Interleukin-4 / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D008814:Mice, Inbred NZB; D016559:Tacrolimus / Q000494:pharmacology*
D008070:Lipopolysaccharides; D015847:Interleukin-4; D007371:Interferon-gamma; D004247:DNA; D016559:Tacrolimus